For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Parkinson's disease

Related

  • FirePlex multiplexing and Parkinson's disease
    • Dopaminergic neuron markers
      • Neural markers guide
        • MLi-2, LRRK2 inhibitor
          • Parkinson's disease interactive pathway
            • Parkinson's disease current and future landscape
              • Alzheimer's disease
                • Huntington's disease
                  • Multiple sclerosis
                    • Amyotrophic lateral sclerosis

                      ​To bring the tools you need for Parkinson’s disease research, we partnered with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop rabbit monoclonal antibodies against promising targets.

                      ​​​​Robust research requires equally robust tools. In the case of understanding disease pathways, such as those in Parkinson’s, this often means antibodies that reliably bind key targets. Unfortunately, many existing antibodies lack sufficient quality control data, are challenging to obtain, or are tied up in convoluted license agreements, restricting their use. 

                      We want to help the Parkinson’s community to overcome those hurdles. Together with MJFF, we have been generating antibodies and making them widely available to the industry as well as academic and non-profit groups to accelerate therapeutic development for Parkinson’s patients.

                      Over 50 products for Parkinson’s disease research have been produced as part of The MJFF-Abcam collaboration. Of these, 24 are RabMAb® rabbit monoclonals – market-leading antibodies due to the quality and value that they provide. Between them, these antibodies cover the four key Parkinson’s target groups of LRRK2, SNCA, DJ-1, RAB 8 & 10. We invite you to learn more about Parkinson’s disease, The MJFF and our collaboration, and the antibodies we have developed in order to give you the edge in your research.    

                      >> Please see here for further information and resources on Parkinson’s disease, to support your research.


                      Overview

                      ​​

                      • What is Parkinson’s disease?
                      • How is The Michael J. Fox Foundation advancing research?
                      • What happens in the brains of people with Parkinson’s disease?
                      • What do we know about the causes of Parkinson’s?
                      • FirePlex seminar with MJFF
                      • Rabbit monoclonal antibodies for Parkinson’s disease research 

                      What is Parkinson’s disease?

                      Parkinson’s is a neurodegenerative condition in which regions of the brain become increasingly more damaged over time. The physical symptoms of Parkinson’s are commonly tremor and reduced movement, but patients can also suffer from depression, balance issues, and problems with sleeping and memory. The disease affects around 6 million people worldwide and, as of yet, there is no known cure.

                      How is The Michael J. Fox Foundation advancing research?

                      The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.

                      Learn more about The Michael J. Fox Foundation

                      What happens in the brains of people with Parkinson’s disease?

                      The hallmark pathologies of Parkinson’s include the loss of dopaminergic neurons from the pars compacta, a portion of the substantia nigra in the midbrain, which results in slowness of movement (bradykinesia), resting tremor and rigidity1. Another hallmark of Parkinson’s is intracellular protein aggregates known as Lewy bodies.

                      Dopaminergic neurons produce the neurotransmitter dopamine, which is responsible for coordinating movement. When these neurons are lost, there is a reduction of dopamine, causing the characteristic motor symptoms of Parkinson’s disease. Motor symptoms normally emerge after the loss of the majority of dopaminergic neurons.

                      Lewy bodies form when misfolded alpha-synuclein protein aggregates into oligomers, forming β-sheet-rich fibrils. Misfolded alpha-synuclein can move between neurons in a prion-like fashion2, where it can act as a template to promote misfolding of normal alpha-synuclein. The accumulation of alpha-synuclein and other proteins is hypothesized to occur before neuronal loss3.

                      Despite Lewy bodies occurring in regions of neuronal loss, it has been difficult to establish whether their presence correlates with cell death. It is unclear whether Lewy bodies are protective or neurotoxic. However, evidence from multiphoton imaging in mice shows selective death of Lewy body-containing neurons4, indicating that their presence is tightly correlated with cellular toxicity and therefore likely to be a pathologically relevant event in the development of Parkinson’s.

                      What do we know about the causes of Parkinson’s?

                      The majority of Parkinson’s cases are sporadic, with less than 10% having a genetic component5. Contributors to Parkinson's disease include oxidative stress and abnormal protein aggregation and degradation.

                      Genetics

                      Mutations in six genes (SNCA, LRRK2, PRKN, DJ1, PINK1, and ATP 13A2) are known to contribute to the development of Parkinson’s6,7. Polymorphisms in three genes (MAPT, LRRK2, and SNCA) and loss-of-function mutations in GBA are also risk factors6.

                      Protein aggregation and misfolding

                      Aggregation and misfolding of alpha-synuclein are believed to be steps in the development of Parkinson’s disease8. Misfolded alpha-synuclein impairs protein caretaking systems, such as the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP). Without these pathways working normally, there is a feedback loop in which alpha-synuclein accumulates, further suppressing UPS or ALP function, leading to neuronal death9,10,11.

                      The transcription factor Lmx1b was shown to be essential for normal ALP function and the integrity and long-term survival of dopaminergic neurons12,13.

                      Oxidative stress

                      Loss of dopamine in Parkinson’s disease causes oxidative stress. Dopamine is normally metabolized by monoamine oxidase (MAO)-B, leading to the generation of hydrogen peroxide. Glutathione normally clears excess hydrogen peroxide from the cell, with failure to do so leading to the production of reactive oxygen species (ROS) capable of initiating a cytotoxic cascade of lipid peroxidation and cell death. Reduced levels of glutathione in Parkinson’s brains14, coupled with a high dopamine turnover (a compensatory mechanism for reduced dopaminergic neurons), lead to high levels of peroxidation and cellular damage.

                      Dopamine-quinone is another product of spontaneous and enzymatic dopamine oxidation. Dopamine-quinone is capable of causing mitochondrial dysfunction or modifying proteins, such as alpha-synuclein, parkin, DJ-1, and UCH-L1, dysfunction of which can lead to Parkinson’s disease pathophysiology15,16.

                      Mitochondrial dysfunction

                      Excessive mitochondrial damage contributes to Parkinson’s pathogenesis. Damage to mitochondria, either as a result of reduced activity of complex I in the electron transport chain, lipid membrane peroxidation by ROS, or genetic-induced alterations, can lead to the release of cytochrome c, triggering apoptosis15,16. Parkin and PINK1, for example, localize to mitochondria and are associated with normal function17. PINK1 accumulates on the outer membrane of damaged mitochondria where it recruits parkin to the dysfunctional mitochondria, triggering mitophagy18. Accumulation of dysfunctional mitochondria can lead to early-onset Parkinson’s18.

                      Neuroinflammation

                      Dopaminergic neurons intrinsically generate high levels of ROS, making them susceptible to this chain of oxidative stress events. The progressive loss of dopaminergic neurons is associated with chronic neuroinflammation through the activation of microglia by proteins such as alpha-synuclein, parkin, LRRK2, and DJ-119,20. Overactive or chronically activated microglia can release ROS21 and cause an uncontrolled inflammatory response, producing a self-perpetuating cycle of neurodegeneration22.

                      LRRK, in particular, is thought to be a key modulator of neuroinflammation23. LRRK is highly induced in response to alpha-synuclein overexpression, while LRRK2 knockout rats are resistant to neuroinflammatory responses and dopaminergic neurodegeneration following alpha-synuclein overexpression24.

                      FirePlex seminar with MJFF

                      Join presenters Dr Nicole Polinski from The Michael J. Fox Foundation (MJFF) for Parkinson's research and Dr Elnaz Atabakhsh from Abcam to learn more about how the FirePlex® multiplex platform is helping to profile neuroinflammatory biomarkers in patient samples.​

                      The webinar covers

                      • Introduction to Parkinson's disease and The Michael J. Fox Foundation (8 minutes)
                      • Importance of investigating inflammation in Parkinson's disease (8 minutes)
                      • Future directions of Parkinson's disease research (30 minutes)
                      • The FirePlex technology platform and biomarker profiling (10 minutes)

                      ​

                      ​​​​​​​

                      Rabbit monoclonal antibodies for Parkinson’s disease research

                      In collaboration with MJFF, we developed antibodies for Parkinson’s research. These are part of a larger catalog of research tools available through MJFF.

                      LRRK2 

                      LRRK2 gene mutations are the most common cause of inherited Parkinson's disease. While it is the focus of intensive research in the Parkinson's field, a lack of high-quality LRRK2 antibodies has been a major roadblock to the successful development of LRRK2-based therapies.

                      After primary characterization organized by MJFF and feedback from the Parkinson’s disease research community, three rabbit monoclonal clones exhibiting the best performance were selected for distribution via Abcam.

                      "LRRK2 antibodies are critical to help move Parkinson's research forward. The three unique clones chosen for initial release were identified based on several months of testing by our large network of Parkinson’s researchers... we are excited that they [Abcam] will continue to help MJFF remove barriers to developing Parkinson's therapies."

                      - Dr Mark Frasier, Vice President of Research Programs at MJFF

                      Antibody name

                      Clone ID

                      Applications

                      Species

                      AbID

                      LRRK2

                      MJFF2
                      (c41-2)

                      ICC/IF, IHC-FrFl, IHC-P, IP, WB 

                      Hu, Ms, Rt

                      ab133474

                      LRRK2

                      MJFF3
                      (c69-6)

                      ICC/IF, IHC-P, IP, WB

                      Hu, Ms, Rt

                      ab133475

                      LRRK2

                      MJFF4 
                      (c81-8)

                      ICC/IF, IHC-P, IP, WB

                      Hu, Ms, Rt

                      ab133476

                      LRRK2
                      ​

                      MJFF5 (68-7)

                      WB

                      Hu, Ms

                      ab181386

                      LRRK2

                      UDD3 30(12)

                      ICC/IF, IHC-P, WB

                      Hu, Ms

                      ab133518

                      LRRK2 
                      (phospho S910)

                      UDD1 15(3)

                      WB

                      Hu

                      ab133449

                      LRRK2 
                      (phospho S935)

                      UDD2 10(12)

                      ICC/IF, WB

                      Hu, Ms

                      ab133450

                      LRRK2 (phospho S955)

                      MJF-R11 (75-1)

                      WB

                      Hu, Ms

                      ab169521

                      LRRK2 (phospho S973)

                      MJF-R12 (37-1)

                      WB

                      Hu

                      ab181364

                      LRRK2 (phospho T1410)

                      MJFR4-25-5

                      WB

                      Hu, Ms, Rt

                      ab140107

                      LRRK2 
                      (phospho T1491)

                      MJFR5-88-3

                      WB

                      Hu

                      ab140106

                      LRRK2 (phospho T1503)

                      MJF-R6
                      (227-1a)

                      WB

                      Hu

                      ab154423

                      LRRK2 (phospho S1292)

                      MJFR-19-7-8

                      WB

                      Hu

                      ab203181

                      LRRK2 (phospho T2483)

                      MJF-R8
                      (21-2e)

                      WB

                      Hu

                      ab156577

                      • See a complete list of LRRK2 antibodies and their characterization data.

                      Alpha-synuclein 

                      SNCA was the first gene to be linked to Parkinson’s disease and remains the most promising link to Parkinson's pathogenesis. Alpha-synuclein, the protein encoded by this gene, is a major component of Lewy bodies, a type of intraneuronal aggregate. The build-up of these aggregates within neurons causes the loss of motor control associated with Parkinson's disease. 

                      Antibody name

                      Clone ID

                      Applications

                      Species

                      AbID

                      Alpha-synuclein

                      MJFR1

                      ELISA, flow cytometry, ICC/IF, IHC-P, IP, WB

                      Hu, Drosophila melanogaster

                      ab138501

                      Alpha-synuclein (phospho S129)

                      MJF-R13
                      (8-8)

                      WB

                      Hu

                      ab168381

                      Alpha-synuclein filament - conformation-specific

                      MJFR-14-6-4-2

                      ICC/IF, IHC-P, dot blot

                      Hu, Ms, Rt

                      ab209538

                      Alpha-synuclein proteins

                      In collaboration with MJFF, we have developed recombinant human alpha-synuclein proteins to help you accelerate your research in PD. These proteins can be used as specific reference material or positive controls in various biochemical assays to study the aggregation of alpha-synuclein.


                      Product name

                      Application

                      Species

                      AbID

                      Recombinant human alpha-synuclein protein filament

                      SDS-PAGE, dot blot

                      Human

                      ab254309

                      Recombinant human alpha-synuclein protein monomer

                      Mass spectrometry, SDS-PAGE, HPLC

                      Human

                      ab254310

                      DJ-1

                      DJ-1 (PARK7) is thought to act as a sensor of oxidative stress in cells. It has increasingly been investigated for modifications that occur as a result of disease pathogenesis, including protein oxidation. DJ-1 is responsible for the activation of microglia leading to neuroinflammation associated with Parkinson's disease. 


                      Antibody name

                      Clone ID

                      Application

                      Species

                      AbID

                      DJ1 (PARK7)

                      MJF-R16
                      (66-5)

                      WB

                      Hu

                      ab169520

                      ​​

                      RAB GTPases

                      Certain Rab GTPases (Rabs) are linked to Parkinson’s disease through disease-associated mutations or interactions with key Parkinson’s disease-related proteins like alpha-synuclein and LRRK2. Given this relationship to Parkinson’s disease and the known role of Rabs in endocytic trafficking, these proteins are important targets for understanding Parkinson’s disease pathobiology and target engagement.


                      Antibody name

                      Clone ID

                      Application

                      Species

                      AbID

                      Anti-RAB8A (phospho T72)

                      [MJF-20-25-2]

                      WB, dot blot

                      Mo, Hu

                      ab230260

                      Anti-RAB10 (phospho T73)

                      [MJF-21-108-10] 

                      WB, dot blot

                      Mo, Hu

                      ab230261

                      Anti-RAB8A 

                      [MJF-22-74-3]

                      WB, IP

                      Mo, Rt, Hu

                      ab237702

                      Anti-RAB8A[MJF-R22-79-3]WB, IHC-P, ICC/IF, flow cytometry, IPHuab241061

                      Anti-RAB10

                      [MJF-23-32-5]

                      IP, flow cytometry, ICC/IF, WB

                      Mo, Rt, Hu

                      ab237703

                      Anti-RAB10 (phospho T73)

                      [MJF-R21-22-5]

                      WB, dot blot, ICC/IF

                      Mo, Hu

                      ab241060

                      Anti-Rab12 (phospho106)[MJF-R25-9]Dot blot, WBMo, Huab256487
                      Anti-Rab29[MJF-30-124]IP, WBMo, Huab256526
                      Anti-Rab29[MJF-30-104]WB, IPHuab256527

                      Anti-RAB29 (phospho T71)
                      ​

                      [MJF-R24-17-1]

                      Dot blot, WB

                      Hu

                      ab241062


                      RAB ELISA kits

                      Antibody name

                      Species

                      AbID

                      Human RAB8 ELISA kit

                      Hu

                      ab255718

                      RAB10 ELISA kit

                      Mo, Rt, Hu

                      ab255717


                      References

                      1. Obeso, J. a, Rodriguez-Oroz, M. C., Stamelou, M., Bhatia, K. P. & Burn, D. J. The expanding universe of disorders of the basal ganglia. Lancet 384, 523–31 (2014).

                      2. Guo, J. L. & Lee, V. M. Y. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20, 130–138 (2014).

                      3. Cheng, H. C., Ulane, C. & Burke, R. Clinical progression in Parkinson’s disease and the neurobiology of Axons. Ann. Neurol. 67, 715–725 (2010).

                      4. Osterberg, V. R. et al. Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 10, 1252–60 (2015).

                      5. Thomas, B. & Beal, M. F. Parkinson’s disease. Hum. Mol. Genet. 16, R183–R194 (2007).

                      6. Bekris, L. M., Mata, I. F. & Zabetian, C. P. The Genetics of Parkinson Disease. 18, 1199–1216 (2013).

                      7. Klein, C. & Westenberger, A. Genetics of Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2, a008888 (2012).

                      8. Irwin, D. J., Lee, V. M.-Y. & Trojanowski, J. Q. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci. 14, 626–36 (2013).

                      9. Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M. & Klionsky, D. J. The Role of Autophagy in Parkinson’s Disease. Cold Spring Harb. Perspect. Med. 2, a009357–a009357 (2012).

                      10. Ciechanover, A. & Kwon, Y. T. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp. Mol. Med. 47, e147 (2015).

                      11. Xilouri, M., Brekk, O. R. & Stefanis, L. Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship. Mol. Neurobiol. 6, 1–15 (2012).

                      12. Laguna, A. et al. Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson’s disease. Nat. Neurosci. 18, 826–835 (2015).

                      13. Isacson, O. Lysosomes to combat Parkinson’s disease. Nat. Neurosci. 18, 792–793 (2015).

                      14. Martin, H. L. & Teismann, P. Glutathione--a review on its role and significance in Parkinson’s disease. FASEB J. 23, 3263–3272 (2009).

                      15. Hwang, O. Role of oxidative stress in Parkinson’s disease. Exp. Neurobiol. 22, 11–7 (2013).

                      16. Blesa, J., Trigo-Damas, I., Quiroga-Varela, A. & Jackson-Lewis, V. R. Oxidative stress and Parkinson’s disease. Front. Neuroanat. 9, 1–9 (2015).

                      17. Scarffe, L. a., Stevens, D. a., Dawson, V. L. & Dawson, T. M. Parkin and PINK1: Much more than mitophagy. Trends Neurosci. 37, 315–324 (2014).

                      18. Pickrell, A. M. & Youle, R. J. The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease. Neuron 85, 257–273 (2015).

                      19. Lee, E.-J. et al. α-Synuclein Activates Microglia by Inducing the Expressions of Matrix Metalloproteinases and the Subsequent Activation of Protease-Activated Receptor-1. J. Immunol. 185, 615–623 (2010).

                      20. Wilhelmus, M. M. M., Nijland, P. G., Drukarch, B., De Vries, H. E. & Van Horssen, J. Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. Free Radic. Biol. Med. 53, 983–992 (2012).

                      21. Block, M. L., Zecca, L. & Hong, J.-S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57–69 (2007).

                      22. Qian, L., Flood, P. M. & Hong, J. S. Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J. Neural Transm. 117, 971–979 (2010).

                      23. Puccini, J. M. et al. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders. J. Neurosci. 35, 5271–83 (2015).

                      24. Daher, J. P. L., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S. & West, A. B. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. U. S. A. 111, 9289–94 (2014).






                      Get resources and offers direct to your inbox Sign up
                      A-Z by research area
                      • Cancer
                      • Cardiovascular
                      • Cell biology
                      • Developmental biology
                      • Epigenetics & Nuclear signaling
                      • Immunology
                      • Metabolism
                      • Microbiology
                      • Neuroscience
                      • Signal transduction
                      • Stem cells
                      A-Z by product type
                      • Primary antibodies
                      • Secondary antibodies
                      • Biochemicals
                      • Isotype controls
                      • Flow cytometry multi-color selector
                      • Kits
                      • Loading controls
                      • Lysates
                      • Peptides
                      • Proteins
                      • Slides
                      • Tags and cell markers
                      • Tools & Reagents
                      Help & support
                      • Support
                      • Make an Inquiry
                      • Protocols & troubleshooting
                      • Placing an order
                      • RabMAb products
                      • Biochemical product FAQs
                      • Training
                      • Browse by Target
                      Company
                      • Corporate site
                      • Investor relations
                      • Company news
                      • Careers
                      • About us
                      • Blog
                      Events
                      • Tradeshows
                      • Conferences
                      International websites
                      • abcam.cn
                      • abcam.co.jp

                      Join with us

                      • LinkedIn
                      • facebook
                      • Twitter
                      • YouTube
                      • Terms of sale
                      • Website terms of use
                      • Cookie policy
                      • Privacy policy
                      • Legal
                      • Modern slavery statement
                      © 1998-2023 Abcam plc. All rights reserved.